Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06585202 · ClinicalTrials.gov registry record · Phase 2
Study of ATI-2138 in Adult Participants With Moderate to Severe Atopic Dermatitis
A Phase 2 study, sponsored by Aclaris Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 14
- Enrollment target
NCT06585202 is a Phase 2 study that has completed, run by Aclaris Therapeutics. The registered enrollment target is 14 participants.
The verdict
NCT06585202, a Phase 2 study, has completed, sponsored by Aclaris Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 14 participants
- Enrollment target
Study Summary
This is a Phase 2 open label study of ATI-2138 in participants with moderate to severe atopic dermatitis.
Interventions
- DRUG ATI-2138
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2024-08-19 |
| Est. Completion | 2025-03-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06585202
The ClinicalTrials.gov registry entry for NCT06585202 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Aclaris Therapeutics, which has 33 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ATI-2138 is the first listed.
NCT06585202 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06585202 about?
NCT06585202 is a clinical study titled "Study of ATI-2138 in Adult Participants With Moderate to Severe Atopic Dermatitis". This is a Phase 2 open label study of ATI-2138 in participants with moderate to severe atopic dermatitis.
What is the current status of trial NCT06585202?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 14 participants. The study started on 2024-08-19. Estimated completion is 2025-03-31.
What interventions are being tested in trial NCT06585202?
The interventions under investigation include: ATI-2138 (DRUG).
Who is sponsoring clinical trial NCT06585202?
This trial is sponsored by Aclaris Therapeutics, which has 33 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.